<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04070157</url>
  </required_header>
  <id_info>
    <org_study_id>USWM-LX1-2010</org_study_id>
    <nct_id>NCT04070157</nct_id>
  </id_info>
  <brief_title>Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal</brief_title>
  <acronym>TAPER</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety and Effectiveness of LUCEMYRA in the Treatment of Opioid Withdrawal During an Opioid Taper in Subjects With Chronic Non-Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US WorldMeds LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>US WorldMeds LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stopping prescription opioid pain medications can be difficult due to withdrawal symptoms.
      This study will test if LUCEMYRA helps reduce withdrawal symptoms and helps more people
      reduce their opioid dose compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blind, placebo-controlled pilot study will evaluate the safety and
      effectiveness of LUCEMYRA in the treatment of opioid withdrawal during an opioid taper in
      subjects with chronic non-cancer pain.

      Subjects will begin a planned 14-day complete taper of their pre-study opioid medications and
      will be randomly assigned (1:1) to either LUCEMYRA or matching placebo. Study drug will be
      administered through the opioid taper and for 5 days after the opioid taper is completed.
      Study drug will then be tapered over a 4-day period for a total of approximately 21 days
      exposure to study drug.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Enrollment on Hold (COVID-19)
  </why_stopped>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All subjects, study personnel (including the Investigator, study coordinator(s), pharmacist/designee), and the Sponsor will be blinded to the identity of the study drug (active or placebo) administered to subjects.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent AEs and SAEs by system organ class and preferred term</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and percent of subjects reporting TEAEs resulting in study drug discontinuation</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with treatment-emergent elevated liver function tests</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects identified as suicide risk with Columbia Suicide Severity Rating Scale</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>Baseline to Days 1, 2, 3, 7, 8, 14, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pulse</measure>
    <time_frame>Baseline to Days 1, 2, 3, 7, 8, 14, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who successfully complete each scheduled dose reduction and the opioid taper to complete opioid discontinuation</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Opiate Withdrawal Scale (COWS)</measure>
    <time_frame>Day 1 (pre-1st dose) to Days 3, 8, 15, 22 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Short Opiate Withdrawal Scale of Gossop (SOWS-G)</measure>
    <time_frame>Day 1 (pre-1st dose) to Days 1 (at bedtime), 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Subjective Opiate WIthdrawal Scale of Handelsman (SOWS-H)</measure>
    <time_frame>Day 1 (pre-1st dose) to Days 1 (at bedtime), 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Clinical Global Impression - Rater Version (MCGI-R)</measure>
    <time_frame>Each scheduled evaluation (Day 1 through Day 28)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Clinical Global Impression - Subject Version (MCGI-S)</measure>
    <time_frame>Each scheduled evaluation (Day 1 through Day 28)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to study drug discontinuation</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non-opioid concomitant medications for withdrawal symptoms used by study day</measure>
    <time_frame>Day 1 through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) scale</measure>
    <time_frame>Baseline to Days 28 and 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form Health Survey (SF-36) scale</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insomnia Severity Index (ISI)</measure>
    <time_frame>Baseline to Days 15 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Chronic Pain as measured by the Numeric Rating Scale (NRS)</measure>
    <time_frame>Baseline through Day 51 (assessed daily)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Overall Pain as measured by the Numeric Rating Scale (NRS)</measure>
    <time_frame>Day 1 through Day 28 (assessed daily)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Worst Chronic Pain as measured by the Numeric Rating Scale (NRS)</measure>
    <time_frame>Baseline through Day 51 (assessed daily)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Worst Overall Pain as measured by the Numeric Rating Scale (NRS)</measure>
    <time_frame>Day 1 through Day 28 (assessed daily)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daily opioid dose expressed as morphine equivalent dose (MED)</measure>
    <time_frame>Baseline through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daily opioid dose as a percentage of the baseline MED</measure>
    <time_frame>Baseline through Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Opioid Withdrawal (Disorder)</condition>
  <arm_group>
    <arm_group_label>Lofexidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine</intervention_name>
    <description>Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.</description>
    <arm_group_label>Lofexidine</arm_group_label>
    <other_name>lofexidine hydrochloride</other_name>
    <other_name>LUCEMYRA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject can provide written informed consent.

          -  Chronic non-cancer pain diagnosis such as low back pain, chronic neck pain,
             osteoarthritis, and prolonged post-surgical pain with daily pain for a minimum of 6
             months.

          -  Self-reported use of prescribed oral opioid medication(s) (tablets, pills or capsules)
             of at least 50 morphine mg equivalent (MME) but no higher than 240 mg MME daily or
             near daily (â‰¥5 days per week) for at least 12 weeks and seeking to discontinue their
             opioid medication.

          -  Willing to be treated with non-opioid treatments for pain (in addition to opioid being
             tapered) for duration of study.

          -  Willing to abstain from alcohol use during the study.

          -  Willing to partner with his or her pain physician on a subject-centered pain
             management plan during the study.

          -  In generally good health, in the opinion of the Investigator, other than the
             underlying chronic pain syndrome

          -  Women of childbearing potential must have a negative pregnancy test at Screening.

          -  Non-pregnant, non-lactating women who are postmenopausal, naturally or surgically
             sterile, or who agree to use acceptable contraceptive methods throughout the course of
             the study.

          -  Other criteria will be discussed in detail with potential subjects by Site
             Investigator

        Exclusion Criteria:

          -  Has a primary diagnosis of complex regional pain syndrome, central neuropathic pain,
             somatoform pain syndromes, acute nerve root compression, any acute or progressive
             infectious, inflammatory, or neurological process.

          -  Taking methadone, buprenorphine, fentanyl rapid acting products, tapentadol, tramadol,
             butorphanol, meperidine, or levorphanol for any reason

          -  Liver disease that requires medication or medical treatment, and/or AST or ALT levels
             greater than 3 x ULN.

          -  Gastrointestinal or renal disease, which would significantly impair absorption,
             metabolism or excretion of study drug, or would require medication or medical
             treatment.

          -  Has a diagnosis of epilepsy or history of seizures.

          -  Cardiovascular abnormalities at Screening and before randomization (stable
             hypertension permitted)

          -  Self-reported or evidence of opioid use disorder (OUD) or other substance use disorder
             within last 12 months

          -  Any severe or unstable psychiatric disorder including post-traumatic stress disorder,
             schizophrenia, bipolar disorder, major depression, substance abuse, or suicidality as
             determined by the Investigator.

          -  Subject answers &quot;yes&quot; to &quot;suicidal ideation&quot; in prior 24 months to any items 1 through
             5 on the C-SSRS, or subject answers &quot;yes&quot; to any lifetime &quot;suicidal behavior&quot; item on
             the C-SSRS.

          -  Any anticipated or scheduled surgery during the study period or within 30 days before
             Screening.

          -  Other criteria will be discussed in detail with potential subjects by site
             Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Peppin, DO</last_name>
    <role>Study Director</role>
    <affiliation>US WorldMeds Contract Medical Monitor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Westview Clinical Research, LLC</name>
      <address>
        <city>Placentia</city>
        <state>California</state>
        <zip>92870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitamed Research</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Research, LLC</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Clinical Research, LLC</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Injury Care Research</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Scientific Innovations</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Clinical Trial Services, Inc.</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otrimed Corporation (Otrimed Clinical Research Center)</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Innovation Pain Therapies Clinic at Brier Creek</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Research, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid Withdrawal Syndrome</keyword>
  <keyword>OWS</keyword>
  <keyword>Opioid taper</keyword>
  <keyword>Opioid withdrawal</keyword>
  <keyword>Opioid reduction</keyword>
  <keyword>Stopping opioids</keyword>
  <keyword>Opioid discontinuation</keyword>
  <keyword>non-opioid pain management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lofexidine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

